137 related articles for article (PubMed ID: 16533185)
1. Correlation between bone scintigraphy and tumor markers in patients with breast carcinoma.
Begić A; Kucukalić-Selimović E; Obralić N; Durić O; Lacević N; Skopljak A
Bosn J Basic Med Sci; 2006 Feb; 6(1):75-7. PubMed ID: 16533185
[TBL] [Abstract][Full Text] [Related]
2. Comparison of bone scintigraphy with serum tumor markers of CA 15-3 and carcinoembryonic antigen in patients with breast carcinoma.
Gedik GK; Kiratli PO; Tascioglu B; Aras T
Saudi Med J; 2006 Mar; 27(3):317-22. PubMed ID: 16532090
[TBL] [Abstract][Full Text] [Related]
3. [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer].
Zissimopoulos A; Petrakis G; Stellos K; Baziotis N
Hell J Nucl Med; 2006; 9(1):60-4. PubMed ID: 16617400
[TBL] [Abstract][Full Text] [Related]
4. Relationship between bone scintigraphy and tumor markers in patients with breast cancer.
Yildiz M; Oral B; Bozkurt M; Cobaner A
Ann Nucl Med; 2004 Sep; 18(6):501-5. PubMed ID: 15515750
[TBL] [Abstract][Full Text] [Related]
5. Role of bone scintigraphy and tumor marker-Ca 15-3 in detection of bone metastases in patients with breast cancer.
Begić A; Kucukalić-Selimović E; Obralić N; Durić O; Lacević N; Begović S; Dzubur-Aganović M
Bosn J Basic Med Sci; 2005 Feb; 5(1):23-6. PubMed ID: 15771599
[TBL] [Abstract][Full Text] [Related]
6. Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: special emphasis on "spiking" phenomena.
Yasasever V; Dinçer M; Camlica H; Karaloğlu D; Dalay N
Clin Biochem; 1997 Feb; 30(1):53-6. PubMed ID: 9056110
[TBL] [Abstract][Full Text] [Related]
7. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy.
Nicolini A; Ferrari P; Sagripanti A; Carpi A
Br J Cancer; 1999 Mar; 79(9-10):1443-7. PubMed ID: 10188888
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
9. Comparison of bone scanning and CA 15-3 serum concentration in the follow-up of breast cancer.
Montravers F; Younsi N; Rousseau C; Philippe C; Seddiki M; Uzan S; Izrael V; Talbot JN
Anticancer Res; 1997; 17(3B):1683-6. PubMed ID: 9179218
[TBL] [Abstract][Full Text] [Related]
10. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis of bone and liver metastases in breast cancer comparing tumor markers and imaging techniques.
Zanco P; Rota G; Sportiello V; Borsato N; Ferlin G
Int J Biol Markers; 1989; 4(2):103-5. PubMed ID: 2768888
[TBL] [Abstract][Full Text] [Related]
12. Association between bone scintigraphy and serum levels of tumor markers in the detection of bone disease in breast cancer patients.
Zissimopoulos A; Matthaios D; Matthaiou E; Mantadakis E; Karaitianos I
J BUON; 2007; 12(4):505-11. PubMed ID: 18067209
[TBL] [Abstract][Full Text] [Related]
13. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease.
Colomer R; Ruibal A; Salvador L
Cancer; 1989 Oct; 64(8):1674-81. PubMed ID: 2790682
[TBL] [Abstract][Full Text] [Related]
15. Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.
Aktas B; Kasimir-Bauer S; Lehmann N; Kimmig R; Tewes M
Oncol Rep; 2013 Jul; 30(1):441-7. PubMed ID: 23604361
[TBL] [Abstract][Full Text] [Related]
16. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
[TBL] [Abstract][Full Text] [Related]
17. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
18. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA.
Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Winkel P; Mouridsen HT; Dombernowsky P
Ann Oncol; 1993 Dec; 4(10):861-9. PubMed ID: 8117606
[TBL] [Abstract][Full Text] [Related]
19. Significance of bone alkaline phosphatase, CA 15-3 and CEA in the detection of bone metastases during the follow-up of patients suffering from breast carcinoma.
Stieber P; Nagel D; Ritzke C; Rössler N; Kirsch CM; Eiermann W; Fateh-Moghadam A
Eur J Clin Chem Clin Biochem; 1992 Dec; 30(12):809-14. PubMed ID: 1489855
[TBL] [Abstract][Full Text] [Related]
20. [Reliability of CA 15-3 in the follow up of female patients with breast carcinoma and bone metastases].
del Rocío Estrada-Sánchez G; Mireles Enríquez M; Valverde Castañeda N
Rev Invest Clin; 2003; 55(4):412-8. PubMed ID: 14635605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
